The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes

International Journal of Oncology

Volumn 48, Issue 4, 2016, Pages 1721-1729

  Zhao, Mengjing ^a   Wei, Cai ^a   Yang, Xue ^a   Zhou, Juan ^a   Wang, Jing ^a   Gu, Fang ^a   Lei, Ting ^a   Qin, Yide ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

gene expression; invasion; migration; ovarian cancer cell; peptide

Indexed keywords

ANTINEOPLASTIC AGENT; HEXAPEPTIDE; MESSENGER RNA; PROLYLGLYCYLPROLYLISOLEUCYLPROLYLASPARGINE; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; NME1 PROTEIN, HUMAN; NUCLEOSIDE DIPHOSPHATE KINASE NM23; OLIGOPEPTIDE; REPRESSOR PROTEIN;

ARTICLE; CANCER CELL; COLONY FORMATION; DRUG MECHANISM; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; MTA1 GENE; NM23H1 GENE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; NEOPLASM INVASIVENESS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; OLIGOPEPTIDES; OVARIAN NEOPLASMS; REPRESSOR PROTEINS;

EID: 84958999470     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3390     Document Type: Article

References (31)

1. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 62: 10-29, 2012.
2. Hennessy BT, Coleman RL, and Markman M. Ovarian cancer. Lancet. 374: 1371-1382, 2009.
3. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al; European Organization for Research, and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 363: 943-953, 2010.
4. Jayson GC, Kohn EC, Kitchener HC, and Ledermann JA. Ovarian cancer. Lancet. 384: 1376-1388, 2014.
5. Baldi A, Ioannis P, Chiara P, Eleonora F, Roubini C, and Vittorio D. Biological effects of milk proteins, and their peptides with emphasis on those related to the gastrointestinal ecosystem. J Dairy Res 72 (S1): 66-72, 2005.
6. Walhout AJ, Sordella R, Lu X, Hartley JL, Temple GF, Brasch MA, Thierry-Mieg N, and Vidal M. Protein interaction mapping in C. elegans using proteins involved in vulval development. Science. 287: 116-122, 2000.
7. Zhou J, Chen J, Mokotoff M, and Ball ED. Targeting gastrinreleasing peptide receptors for cancer treatment. Anticancer Drugs. 15: 921-927, 2004.
8. Mader JS, and Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs. 15: 933-946, 2006.
9. Wang W, Gu F, Wei C, Tang Y, Zheng X, Ren M, and Qin Y. PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2. PLoS One. 8: e60701, 2013.
10. Fiat AM, Migliore-Samour D, Jollès P, Drouet L, Bal dit Sollier C, and Caen J. Biologically active peptides from milk proteins with emphasis on two examples concerning antithrombotic, and immunomodulating activities. J Dairy Sci. 76: 301-310, 1993.
11. Ganjam LS, Thornton WH Jr, Marshall RT, and MacDonald RS. Antiproliferative effects of yogurt fractions obtained by membrane dialysis on cultured mammalian intestinal cells. J Dairy Sci. 80: 2325-2329, 1997.
12. Kayser H, and Meisel H. Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins. FEBS Lett. 383: 18-20, 1996.
13. Meisel H. Biochemical properties of regulatory peptides derived from milk proteins. Biopolymers. 43: 119-128, 1997.
14. Meisel H, and FitzGerald RJ. Biofunctional peptides from milk proteins: Mineral binding, and cytomodulatory effects. Curr Pharm Des. 9: 1289-1295, 2003.
15. Livak KJ, and Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR, and the 2(-Delta Delta C(T)) method. Methods. 25: 402-408, 2001.
16. Green MR, and Sambrook J. Molecular Cloning: A Laboratory Manual. 4th edition. Cold Spring Habor Laboratory Press, New York, NY, 2012.
17. Chi JY, Hsiao YW, Li CF, Lo YC, Lin ZY, Hong JY, Liu YM, Han X, Wang SM, Chen BK, et al. Targeting chemotherapyinduced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers. Oncotarget. 6: 23987-24001, 2015.
18. Shan D, Li J, Cai P, Prasad P, Liu F, Rauth AM, and Wu XY. RGD-conjugated solid lipid nanoparticles inhibit adhesion, and invasion of avβ3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 5: 15-26, 2015.
19. Chen HY, Mollstedt O, Tsai MH, and Kreider RB. Potential clinical applications of multi-functional milk proteins, and peptides in cancer management. Curr Med Chem. 21: 2424-2437, 2014.
20. Nongonierma AB, and FitzGerald RJ. Bioactive properties of milk proteins in humans: A review. Peptides. 73: 20-34, 2015.
21. Bonuccelli G, Castello-Cros R, Capozza F, Martinez-Outschoorn UE, Lin Z, Tsirigos A, Xuanmao J, Whitaker-Menezes D, Howell A, Lisanti MP, et al. The milk protein a-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth, and metastasis. Cell Cycle. 11: 3972-3982, 2012.
22. Terasaki-Fukuzawa Y, Kijima H, Suto A, Takeshita T, Iezumi K, Sato S, Yoshida H, Sato T, Shimbori M, and Shiina Y. Decreased nm23 expression, but not Ki-67 labeling index, is significantly correlated with lymph node metastasis of breast invasive ductal carcinoma. Int J Mol Med. 9: 25-29, 2002.
23. Pencil SD, Toh Y, and Nicolson GL. Candidate metastasisassociated genes of the rat 13762NF mammary adenocarcinoma. Breast Cancer Res Treat. 25: 165-174, 1993.
24. Toh Y, Pencil SD, and Nicolson GL. A novel candidate metastasis-Associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression and protein analyses. J Biol Chem. 269: 22958-22963, 1994.
25. Toh Y, Pencil SD, and Nicolson GL. Analysis of the complete sequence of the novel metastasis-Associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma, and breast cancer cell lines. Gene. 159: 97-104, 1995.
26. Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, Nicolson GL, and Sugimachi K. Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion, and metastasis. Int J Cancer. 74: 459-463, 1997.
27. Futamura M, Nishimori H, Shiratsuchi T, Saji S, Nakamura Y, and Tokino T. Molecular cloning, mapping and characterization of a novel human gene, MTA1-L1, showing homology to a metastasis-Associated gene, MTA1. J Hum Genet. 44: 52-56, 1999.
28. Liu H, Mao H, and Fu X. Expression of nm23 in breast cancer: Correlation with distant metastasis, and prognosis. Zhonghua Zhong Liu Za Zhi. 23: 224-227, 2001 (In Chinese
29. Huang G, Song Y, and He G. mRNA expression, and mutation of MTA1, and nm23H1 genes in ovarian carcinoma in relation to lymph node metastasis. Zhonghua Zhong Liu Za Zhi. 23: 31-34, 2001 (In Chinese).
30. Kreider RB, Iosia M, Cooke M, Hudson G, Rasmussen C, Chen H, Mollstedt O, and Tsai MH. Bioactive properties, and clinical safety of a novel milk protein peptide. Nutr J. 10: 99, 2011.
31. Fiedorowicz E, Jarmolowska B, Iwan M, Kostyra E, Obuchowicz R, and Obuchowicz M. The influence of μ-opioid receptor agonist, and antagonist peptides on peripheral blood mononuclear cells (PBMCs). Peptides. 32: 707-712, 2011.